Does Tirzepatide Make You Tired? Fatigue Rates by Dose, Timing and Causes
Fatigue rates on the tirzepatide labels, by dose
The Zepbound table pools two placebo controlled weight loss trials, SURMOUNT-1 and SURMOUNT-2, and lists reactions seen in at least 2% of tirzepatide patients and more often than on placebo. The Mounjaro table pools two type 2 diabetes trials (SURPASS-1 and SURPASS-5) with a 5% cut-off, which is why fatigue appears on one label table and not the other. The last column is our arithmetic: 15 mg rate minus placebo rate, in percentage points.
| Zepbound Table 1 (N 958 / 630 / 948 / 941) | Placebo | 5 mg | 10 mg | 15 mg | 15 mg minus placebo |
|---|---|---|---|---|---|
| Fatigue (asthenia, fatigue, lethargy, malaise) | 3% | 5% | 6% | 7% | +4 |
| Nausea | 8% | 25% | 29% | 28% | +20 |
| Diarrhoea | 8% | 19% | 21% | 23% | +15 |
| Vomiting | 2% | 8% | 11% | 13% | +11 |
| Dizziness | 2% | 4% | 5% | 4% | +2 |
| Hypotension (low blood pressure, including on standing) | 0% | 1% | 1% | 2% | +2 |
Two more label figures. The Mounjaro label lists fatigue at 10% in a cardiovascular outcomes trial of 6,647 adults; that trial, SURPASS-CVOT, compared tirzepatide with dulaglutide, so the 10% is not an effect over placebo and the label gives no dulaglutide rate. And the Zepbound label links low blood pressure to fluid loss: hypotension occurred in 1.6% against 0.1% on placebo, and also "in association with gastrointestinal adverse events and dehydration".
When it happens: dose steps and timing
| Fact | What the source says | Source |
|---|---|---|
| Starting dose and steps | 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks on the current dose | Zepbound and Mounjaro labels, dosage section |
| Time to steady state | 4 weeks of once weekly dosing | Zepbound label, clinical pharmacology |
| Elimination half-life | About 5 days (Mounjaro); 5 to 6 days in overweight or obesity (Zepbound) | Labels, clinical pharmacology |
| Stomach emptying | "The delay is largest after the first dose and this effect diminishes over time" | Zepbound label |
| Stomach side effects | "The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time" | Zepbound label, section 6.1 |
| Stopping because of side effects | Most who stopped for adverse reactions did so "during the first few months" | Zepbound label, section 6.1 |
Neither label reports when fatigue started or how long it lasted, so this page does not invent a number of weeks. As reasoning rather than data: tiredness driven by nausea, eating less or fluid loss should cluster in the same weeks as those effects and ease with them. Tiredness that stays constant at a dose held for months points to the slower causes below. The full escalation schedule is in the tirzepatide dosage guide, and the slower titration some people discuss is in microdosing tirzepatide.
Why it happens: causes and their evidence
Neither label explains the mechanism behind the fatigue row. These are the candidates with a direct basis in the labels or NIH sources. More than one can apply at once, and each can be checked.
| Pattern | Possible cause | Evidence |
|---|---|---|
| Tired in the weeks after starting or a dose step, with nausea, vomiting or diarrhoea | Eating much less; fluid loss | Tirzepatide reduced appetite versus placebo over 28 weeks (Heise 2023). Zepbound section 5.3: most kidney injury cases followed stomach reactions that led to dehydration. MedlinePlus lists headache in mild dehydration and dizziness and listlessness in severe dehydration |
| Headache, muscle weakness, nausea or confusion after days of vomiting or diarrhoea | Low blood sodium | MedlinePlus lists fatigue, headache and muscle weakness as symptoms and vomiting and diarrhoea as causes. Not reported as a tirzepatide adverse reaction, so a blood test question, not a known common effect |
| Shaky, sweaty or confused, while also on insulin or a sulfonylurea | Low blood sugar | Plasma glucose below 54 mg/dL: 4.2% on Zepbound against 1.3% on placebo in SURMOUNT-2, and 10.3% with a sulfonylurea against 2.1% without. In SURMOUNT-1 (no diabetes) 0.3% against none. MedlinePlus lists fatigue or weakness among the symptoms. The label says the risk may be lowered by reducing the insulin or sulfonylurea dose, a prescriber decision |
| Weak rather than sleepy, building over months | Muscle loss, low protein intake | The 2025 joint advisory cites modelling that muscle is 10% to 15% of weight lost in women and 20% to 25% in men without strength training. The labels do not measure it |
| Steady fatigue at a stable dose that food and fluids do not fix | Nutrient shortfall, anaemia, thyroid | The advisory names iron, calcium, magnesium, zinc and vitamins A, D, E, K, B1, B12 and C as nutrients of concern, with "fatigue beyond expected levels" a sign of deficiency, especially below 1,200 kcal a day for women and 1,800 for men. MedlinePlus lists anaemia, iron deficiency and thyroid problems as common causes of fatigue |
A practical trap, as general reasoning: when appetite is suppressed it no longer warns you that you have eaten too little. The advisory recommends reassessing nutrient levels during treatment, and gives 0.8 g/kg/day as the general adult protein allowance, 1.2 to 1.6 g/kg/day as a proposed range during active weight reduction, and an absolute 80 to 120 g a day as a simpler target. It also recommends strength training at least three times weekly plus 150 minutes of moderate aerobic exercise. For ideas on eating with a small appetite see what to eat on semaglutide, which applies here too.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutesResearch vials: check the dose
If you use research vials rather than a branded pen, a reconstitution or syringe reading error can leave you taking more than intended, and nausea, vomiting and diarrhoea all rise with dose in the Zepbound table. Verify the draw with the tirzepatide dosage calculator and confirm your syringe reading against how to read an insulin syringe. Technique is in where to inject tirzepatide. Alcohol and tirzepatide are covered in tirzepatide and alcohol.
When to talk to a doctor
Most tiredness on tirzepatide is mild. Nausea, vomiting or diarrhoea that does not stop, or little or no urine, is the combination the labels tie to kidney injury from dehydration (0.5% against 0.2% on placebo in the Zepbound pool), and the Zepbound label asks prescribers to monitor kidney function in people with reactions that could cause volume depletion, especially during initiation and dose escalation. Shaky, sweaty, confused episodes on insulin or a sulfonylurea can be low blood sugar. The other serious warnings, with their signs, are set out in tirzepatide side effects. MedlinePlus lists confusion, dizziness, blurred vision, little or no urine and thoughts of self-harm as reasons to contact a provider right away, and unexplained fatigue with fever or regular sweats, or feeling sad or depressed, as reasons to book an appointment.
Best vendor for tirzepatide right now: Amino Club
30mg vial, $59.99 per vial ($2.00 per mg), list price checked 2026-09-08. The vendor Bureau readers order from most, with a batch COA on every product page. Partner code 100 at checkout takes 20% off there, and keeps the order counted for the Bureau. Research use only.
Check price at Amino Club Compare all vendorsThe vendor scoring behind the box above is in the vendor scorecard, and the sourcing routes are compared in where to buy tirzepatide.
See also: tirzepatide constipation.
Frequently Asked Questions
Does tirzepatide make you tired?
In a minority of people. In the pooled Zepbound weight loss trials (SURMOUNT-1 and SURMOUNT-2), fatigue, a grouped term that includes asthenia, lethargy and malaise, was reported by 5% on 5 mg, 6% on 10 mg and 7% on 15 mg, against 3% on placebo. Sleepiness is not a listed reaction.
How common is fatigue on tirzepatide?
On the Zepbound label, 5% to 7% depending on dose against 3% on placebo, about 2 to 4 extra people in every 100. The Mounjaro label reports fatigue in 10% of people in its cardiovascular outcomes trial, but that trial compared tirzepatide with dulaglutide and the label gives no comparator rate.
Is tirzepatide fatigue worse at higher doses?
Slightly, on the Zepbound label: 5%, 6% and 7% at 5, 10 and 15 mg. The label reports no statistical test for that trend. Vomiting, which can cause fluid loss, rises more steeply in the same table: 8%, 11% and 13% against 2% on placebo.
How long does tirzepatide fatigue last?
Neither label says. They report that most nausea, vomiting and diarrhoea happened during dose escalation and decreased over time, and that most people who stopped because of side effects did so in the first few months. Tiredness that follows those effects would plausibly ease with them, but that is an inference. Fatigue that persists at a stable dose is worth a blood test.
Does Mounjaro cause fatigue?
Fatigue is not in the Mounjaro label's main adverse reaction table, which lists only reactions seen in at least 5% of Mounjaro patients in the SURPASS-1 and SURPASS-5 placebo controlled trials. Mounjaro and Zepbound are the same molecule, tirzepatide, and the Zepbound table, which uses a 2% cut-off, does list fatigue.
What helps with tirzepatide fatigue?
Start with the causes the labels support: fluid loss from stomach side effects, eating much less, and low blood sugar in people also taking insulin or a sulfonylurea. A 2025 joint nutrition advisory recommends adequate protein and strength training at least three times a week during GLP-1 therapy. Fatigue that does not improve is a reason to check iron, B12 and thyroid with a clinician.
Sources
- Zepbound (tirzepatide) prescribing information, Eli Lilly via DailyMed, revised 8/2026
- Mounjaro (tirzepatide) prescribing information, Eli Lilly via DailyMed, revised 8/2026
- Jastreboff AM et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), N Engl J Med 2022, PMID 35658024
- Garvey WT et al., Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2), Lancet 2023, PMID 37385275
- Sattar N et al., SURPASS-CVOT versus REWIND imputed placebo analysis, Diabetes Care 2026, PMID 41940793 (confirms SURPASS-CVOT compared tirzepatide with dulaglutide)
- Heise T et al., Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes, Diabetes Care 2023, PMID 36857477
- Mozaffarian D et al., Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory, Obesity 2025;33(8):1475-1503
- Fatigue, MedlinePlus Medical Encyclopedia
- Dehydration, MedlinePlus Medical Encyclopedia
- Low blood sodium, MedlinePlus Medical Encyclopedia
- Low blood sugar, MedlinePlus Medical Encyclopedia
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutes